Thirty Years of the Human Immunodeficiency Virus Epidemic and Beyond

Overview

Journal Int J Oral Sci

Date 2013 Oct 19

PMID 24136672

Citations 5

Authors

Fariba S Younai

Affiliations

Soon will be listed here.

Abstract

After more than 30 years of battling a global epidemic, the prospect of eliminating human immunodeficiency virus (HIV) as the most challenging infectious disease of the modern era is within our reach. Major scientific discoveries about the virus responsible for this immunodeficiency disease state, including its pathogenesis, transmission patterns and clinical course, have led to the development of potent antiretroviral drugs that offer great hopes in HIV treatment and prevention. Although these agents and many others still in development and testing are capable of effectively suppressing viral replication and survival, the medical management of HIV infection at the individual and the population levels remains challenging. Timely initiation of antiretroviral drugs, adherence to the appropriate therapeutic regimens, effective use of these agents in the pre and post-exposure prophylaxis contexts, treatment of comorbid conditions and addressing social and psychological factors involved in the care of individuals continue to be important considerations.

Citing Articles

Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma.

De Nicolo A, Manca A, Ianniello A, Palermiti A, Calcagno A, Ferrara M Pharmaceuticals (Basel). 2021; 14(5).

PMID: 34068180 PMC: 8153023. DOI: 10.3390/ph14050460.

Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV.

De Nicolo A, Ianniello A, Ferrara M, Avataneo V, Cusato J, Antonucci M Pharmaceuticals (Basel). 2020; 14(1).

PMID: 33375547 PMC: 7824452. DOI: 10.3390/ph14010012.

Variations in plantar pressure and balance in HIV-infected children in antiretroviral therapy.

da Silva Pontes L, Callegari B, Magno L, Moraes A, Silva B, Manso K Sci Rep. 2019; 9(1):4344.

PMID: 30867540 PMC: 6416285. DOI: 10.1038/s41598-019-41028-0.

Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy.

Kumar P, Lakshmi Y, Kondapi A Pharm Res. 2016; 34(2):257-268.

PMID: 27928647 DOI: 10.1007/s11095-016-2048-4.

Highly Accurate Structure-Based Prediction of HIV-1 Coreceptor Usage Suggests Intermolecular Interactions Driving Tropism.

Kieslich C, Tamamis P, Guzman Y, Onel M, Floudas C PLoS One. 2016; 11(2):e0148974.

PMID: 26859389 PMC: 4747591. DOI: 10.1371/journal.pone.0148974.

References

Barre-Sinoussi F, Chermann J, Rey F, Nugeyre M, Chamaret S, Gruest J . Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983; 220(4599):868-71. DOI: 10.1126/science.6189183. View

Walensky R . Combination HIV prevention: the value and interpretation of mathematical models. Curr HIV/AIDS Rep. 2013; 10(3):195-8. PMC: 3784635. DOI: 10.1007/s11904-013-0167-7. View

Harris C, Small C, Klein R, Friedland G, Moll B, Emeson E . Immunodeficiency in female sexual partners of men with the acquired immunodeficiency syndrome. N Engl J Med. 1983; 308(20):1181-4. DOI: 10.1056/NEJM198305193082001. View

Gutierrez C, Diaz L, Vallejo A, Hernandez-Novoa B, Abad M, Madrid N . Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One. 2011; 6(12):e27864. PMC: 3234247. DOI: 10.1371/journal.pone.0027864. View

Lipman M, Breen R . Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis. 2005; 19(1):20-5. DOI: 10.1097/01.qco.0000200543.80712.01. View

Mazzeo C, Flanagan E, Bobrow E, Pitter C, Marlink R . How the global call for elimination of pediatric HIV can support HIV-positive women to achieve their pregnancy intentions. Reprod Health Matters. 2012; 20(39 Suppl):90-102. DOI: 10.1016/S0968-8080(12)39636-5. View

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

Hammer S, Eron Jr J, Reiss P, Schooley R, Thompson M, Walmsley S . Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008; 300(5):555-70. DOI: 10.1001/jama.300.5.555. View

Friis-Moller N, Reiss P, Sabin C, Weber R, Monforte A, El-Sadr W . Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356(17):1723-35. DOI: 10.1056/NEJMoa062744. View

10.

Popovic M, Sarngadharan M, Read E, Gallo R . Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984; 224(4648):497-500. DOI: 10.1126/science.6200935. View

11.

Alkhatib G, Combadiere C, Broder C, Feng Y, Kennedy P, Murphy P . CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996; 272(5270):1955-8. DOI: 10.1126/science.272.5270.1955. View

12.

Gao G, Wieczorek L, Peachman K, Polonis V, Alving C, Rao M . Designing a soluble near full-length HIV-1 gp41 trimer. J Biol Chem. 2012; 288(1):234-46. PMC: 3537018. DOI: 10.1074/jbc.M112.424432. View

13.

. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep. 2012; 61(31):586-9. View

14.

Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K . Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360(7):692-8. DOI: 10.1056/NEJMoa0802905. View

15.

Hwang S, Boyle T, Lyerly H, Cullen B . Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science. 1991; 253(5015):71-4. DOI: 10.1126/science.1905842. View

16.

Santiago M, Range F, Keele B, Li Y, Bailes E, Bibollet-Ruche F . Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Taï Forest, Côte d'Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2. J Virol. 2005; 79(19):12515-27. PMC: 1211554. DOI: 10.1128/JVI.79.19.12515-12527.2005. View

17.

Hunt P, Brenchley J, Sinclair E, McCune J, Roland M, Page-Shafer K . Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008; 197(1):126-33. PMC: 3466592. DOI: 10.1086/524143. View

18.

Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B . Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2008; 27(6):884-90. DOI: 10.1200/JCO.2008.19.6626. View

19.

Barouch D . Challenges in the development of an HIV-1 vaccine. Nature. 2008; 455(7213):613-9. PMC: 2572109. DOI: 10.1038/nature07352. View

20.

Hu G, Li X, Zhang X, Li Y, Ma L, Yang L . Discovery of inhibitors to block interactions of HIV-1 integrase with human LEDGF/p75 via structure-based virtual screening and bioassays. J Med Chem. 2012; 55(22):10108-17. DOI: 10.1021/jm301226a. View